Capital Fund Management (CFM)
PGNX

Capital Fund Management (CFM)’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Capital Fund Management (CFM)’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-24,600
Closed -$181K – 2061
2017
Q3 		$181K Buy
+24,600
New +$156K ﹤0.01% 1464
2015
Q3 		– Sell
-71,592
Closed -$534K – 1763
2015
Q2 		$534K Sell
71,592
-34,108
-32% -$206K 0.01% 1058
2015
Q1 		$632K Buy
+105,700
New +$665K 0.01% 952

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $637M AUM 39.08% 1-Year Est. Return

Capital Fund Management (CFM)'s PGNX Position: Q4 2017 in Review

Capital Fund Management (CFM) sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2017, closing a stake of 24,600 shares — an estimated $181K sold.

Capital Fund Management (CFM) first reported a position in PGNX in Q1 2015 and held it in 3 quarters. The position peaked at $632K in Q1 2015. 153 funds tracked by Wall St. Rank hold PGNX as of Q4 2017.

  • Capital Fund Management (CFM) reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 24,600 Progenics Pharmaceuticals Inc shares in Q4 2017, an estimated $181K.
  • Capital Fund Management (CFM) first reported a position in Progenics Pharmaceuticals Inc in Q1 2015 and held it in 3 quarters.
  • Capital Fund Management (CFM)'s Progenics Pharmaceuticals Inc position peaked at $632K in Q1 2015.
  • 153 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2017.

Based on Capital Fund Management (CFM)'s 13F filing for Q4 2017, filed 9 Feb 2018.